Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

This study has been completed.
Sponsor:
Information provided by:
BioWest Therapeutics Inc
ClinicalTrials.gov Identifier:
NCT00027248
First received: November 29, 2001
Last updated: September 12, 2005
Last verified: September 2005

November 29, 2001
September 12, 2005
September 2000
Not Provided
Reduction of catheter-related bloodstream infection
Not Provided
Complete list of historical versions of study NCT00027248 on ClinicalTrials.gov Archive Site
  • Reduction of catheter colonization
  • Reduction of local catheter site infection
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization

Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).

BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.

MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • Sepsis
  • Bacteremia
  • Fungemia
Drug: MBI 226
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1400
July 2003
Not Provided

Inclusion Criteria:

  • Patients undergoing non-cuffed arterial and/or central venous catheterization.
  • Patients able to give signed informed consent.
  • Concurrent antibiotic therapy is permitted.

Exclusion Criteria:

  • Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days.
  • Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance.
  • Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days.
  • Second or third degree burn patients.
  • Patients with a suspected or known bloodstream infection or local catheter insertion site infection.
  • Patients with a known allergy to adhesive tape or adhesive bandages.
  • Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study.
  • Routine non-complicated post-operative CABG patients.
  • The disinfection procedure for catheter insertion did not include povidone-iodine.
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00027248
226-98-002
Not Provided
Not Provided
BioWest Therapeutics Inc
Not Provided
Study Director: Jim Pankovich BioWest Therapeutics Inc
BioWest Therapeutics Inc
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP